Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649588 | 0.79 | TGFBR1 (0.47) | ADORA2AMAP3K14PIK3CAMTORTGFBR1 | |
| SCHEMBL1614377 | 0.78 | ADORA2A (0.47) | ADORA2AMAP3K14PIK3CAMTORTGFBR1 | |
| SCHEMBL12850103 | 0.78 | ADORA2A (0.45) | ADORA2AMAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL21084989 | 0.78 | TGFBR1 (0.51) | TGFBR1 | |
| SCHEMBL15639434 | 0.78 | PIK3CA (0.45) | ADORA2AMAP3K14PIK3CAMTORTGFBR1 | |
| SCHEMBL3845576 | 0.78 | ADORA2A (0.45) | ADORA2AMAP3K14TGFBR1CLK1GAA | |
| SCHEMBL4252029 | 0.78 | TGFBR1 (0.39) | TGFBR1CLK1EPHB3 | |
| SCHEMBL13874343 | 0.77 | ADORA2A (0.45) | ADORA2APIK3CAMTORTGFBR1CLK1 | |
| SCHEMBL6220902 | 0.77 | MAP3K14 (0.43) | ADORA2AMAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL6220907 | 0.77 | MAP3K14 (0.43) | ADORA2AMAP3K14PIK3CAMTORFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-12-09 | — | — | US | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | PIKFYVE, JAK3, PI4KA | ADORA2A 1079/4885MAP3K14 56/4885PIK3CA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.